Autoimmune Disease

PUBLISHER: 360iResearch | PRODUCT CODE: 1586171

PUBLISHER: 360iResearch | PRODUCT CODE: 1586171

Celiac Disease Drugs Market by Drug (First Line of Treatment, Second Line of Treatment), Type (Steroids & Immunosuppressive Drugs, Therapeutic Vaccines, Vitamins & Dietary Supplements), Indication, End-User - Global Forecast 2025-2030

PUBLISHED: October 31, 2024

PAGES: 195 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Celiac Disease Drugs Market was valued at USD 1.42 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 10.59%, to USD 2.87 billion by 2030.

Celiac Disease Drugs market research involves analyzing pharmaceuticals aimed at managing and potentially treating Celiac disease, an autoimmune disorder where gluten ingestion damages the small intestine. The scope covers drugs that either alleviate symptoms, promote mucosal healing, or are in development for immune modulation. The necessity for these drugs is driven by the increasing prevalence of diagnosed Celiac cases, expanding gluten-free lifestyle awareness, and the unmet need beyond a strict gluten-free diet. Key applications include pharmaceuticals for symptomatic relief and immune modulation therapies. End-use scopes involve hospitals, research institutions, and specialty clinics.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.42 billion
Estimated Year [2024]	USD 1.56 billion
Forecast Year [2030]	USD 2.87 billion
CAGR (%)	10.59%

Market growth is influenced by rising healthcare expenditures, advancements in biotechnology, and heightened patient and physician awareness. However, substantial opportunities lie in the high demand for non-dietary therapeutics. Pharmaceutical companies can capitalize on innovative drug formulations and combination therapies. Expanding R&D investments and expediting drug approval processes through collaborative partnerships with regulatory authorities could enhance market potential. Challenges include stringent regulatory hurdles, high costs of drug development, and limited comprehensive clinical trial data demonstrating long-term efficacy and safety of emerging treatments. Additionally, the inherent complexity of autoimmune pathophysiology poses complications in drug design.

For growth, innovation should focus on personalized medicine approaches, exploring genetic component interactions with therapeutics, and enhancing patient compliance through alternative drug delivery systems such as oral biologics. Insightful consumer data analytics could redirect R&D towards specific subgroups, potentially changing standard care practices. The market's nature is competitive yet promising, with increased mergers and partnerships anticipated as firms strive to diversify portfolios and leverage biotechnological advancements. Businesses should actively monitor regulatory trends and consider strategic alliances to integrate emerging technologies like genomics and drug delivery systems to accelerate drug development pipelines. Addressing affordability and access remains crucial for wider adoption and sustainability in evolving market dynamics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Celiac Disease Drugs Market

The Celiac Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Growth in prevalence of celiac disease
- Rising dependence of gluten containing and ready-to-eat packaged food
- Increase government and private organizations support towards celiac disease awareness
Market Restraints
- Restricted availability of treatment options
Market Opportunities
- Rising R&D activities to introduce advanced celiac disease drugs
- Technological advancements and increasing modernization in the healthcare sector
Market Challenges
- Strict government regulations for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Celiac Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Celiac Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Celiac Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Celiac Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Celiac Disease Drugs Market

A detailed market share analysis in the Celiac Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Celiac Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Celiac Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Celiac Disease Drugs Market

A strategic analysis of the Celiac Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Celiac Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., Amneal Pharmaceuticals LLC, AMYRA Biotech AG, Artielle Immunotherapeutics Inc., BioLineRx Ltd., Bristol Myers Squibb Company, Calypso Biotech SA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Inovera Bioscience, Johnson & Johnson Services, Inc, Pfizer Inc., Precigen Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., Vactech Oy, and Zedira GmbH.

Market Segmentation & Coverage

This research report categorizes the Celiac Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Drug, market is studied across First Line of Treatment and Second Line of Treatment.
Based on Type, market is studied across Steroids & Immunosuppressive Drugs, Therapeutic Vaccines, and Vitamins & Dietary Supplements.
Based on Indication, market is studied across Anorexia, Bloating, Diarrhea, Distension, Fatigue, and Gas.
Based on End-User, market is studied across Clinical Research Organizations, Hospitals & Clinics, and Research & Academic Institutes.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-4659C87123C2

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growth in prevalence of celiac disease
  - 5.1.1.2. Rising dependence of gluten containing and ready-to-eat packaged food
  - 5.1.1.3. Increase government and private organizations support towards celiac disease awareness
- 5.1.2. Restraints
  - 5.1.2.1. Restricted availability of treatment options
- 5.1.3. Opportunities
  - 5.1.3.1. Rising R&D activities to introduce advanced celiac disease drugs
  - 5.1.3.2. Technological advancements and increasing modernization in the healthcare sector
- 5.1.4. Challenges
  - 5.1.4.1. Strict government regulations for drug approval
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Celiac Disease Drugs Market, by Drug

6.1. Introduction
6.2. First Line of Treatment
6.3. Second Line of Treatment

7. Celiac Disease Drugs Market, by Type

7.1. Introduction
7.2. Steroids & Immunosuppressive Drugs
7.3. Therapeutic Vaccines
7.4. Vitamins & Dietary Supplements

8. Celiac Disease Drugs Market, by Indication

8.1. Introduction
8.2. Anorexia
8.3. Bloating
8.4. Diarrhea
8.5. Distension
8.6. Fatigue
8.7. Gas

9. Celiac Disease Drugs Market, by End-User

9.1. Introduction
9.2. Clinical Research Organizations
9.3. Hospitals & Clinics
9.4. Research & Academic Institutes

10. Americas Celiac Disease Drugs Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Celiac Disease Drugs Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Celiac Disease Drugs Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AbbVie Inc.
2. Adaptive Biotechnologies Corp.
3. Almirall SA
4. Amgen Inc.
5. Amneal Pharmaceuticals LLC
6. AMYRA Biotech AG
7. Artielle Immunotherapeutics Inc.
8. BioLineRx Ltd.
9. Bristol Myers Squibb Company
10. Calypso Biotech SA
11. GlaxoSmithKline PLC
12. Glenmark Pharmaceuticals Ltd.
13. Inovera Bioscience
14. Johnson & Johnson Services, Inc
15. Pfizer Inc.
16. Precigen Inc.
17. Sanofi S.A.
18. Takeda Pharmaceutical Co. Ltd.
19. Vactech Oy
20. Zedira GmbH

Product Code: MRR-4659C87123C2

LIST OF FIGURES

FIGURE 1. CELIAC DISEASE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CELIAC DISEASE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. CELIAC DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CELIAC DISEASE DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FIRST LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SECOND LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY STEROIDS & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY VITAMINS & DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ANOREXIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BLOATING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FATIGUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 39. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 43. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 61. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 65. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 73. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 97. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 110. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 114. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 118. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 134. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 146. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 150. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 154. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 182. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ